OxMIF as a diagnostic marker
View Patent ↗The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.
1. A method for in vitro diagnosis of a disease related to the presence of oxMIF in a subject, said method comprising:
a) contacting a sample from said subject with an anti-oxMIF antibody wherein said antibody binds oxMIF but not redMIF;
wherein said antibody is selected from the group consisting of:
i. a RAB4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25110 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25112,
ii. a RAB9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25111 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25113,
iii. a RAB0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25114 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25115,
iv. a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6,
v. a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5,
vi. a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7, and
b) detecting the presence of oxMIF in said sample by detecting the binding of said anti-oxMIF antibody to said sample, wherein binding of said anti-oxMIF antibody to said sample is indicative of the presence of oxMIF in said sample, and wherein the presence of a higher level of oxMIF in said sample as compared to the level of oxMIF in a healthy control is indicative of the presence of a MIF-related disease in said sample.
2. The method according to claim 1 , wherein said sample is a body fluid sample of said subject.
3. The method according to claim 1 , wherein said sample is a cellular sample of said subject.
4. The method of claim 1 wherein said antibody is a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6.
5. The method of claim 1 wherein said antibody is a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5.
6. The method of claim 1 wherein said antibody is a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7.
7. A composition comprising an anti-MIF antibody, wherein said antibody is selected from the group consisting of:
a) a RAB4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25110 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25112,
b) a RAB9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25111 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25113, and
c) a RAB0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25114 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25115.
8. A composition comprising an anti-MIF antibody, wherein said antibody is selected from the group consisting of:
a) a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6,
b) a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5, and
c) a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7.
9. The composition of claim 8 , wherein said antibody is a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6.
10. The composition of claim 8 , wherein said antibody is a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5.
11. The composition of claim 8 , wherein said antibody is a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7.